Compare IBEX & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | SLDB |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.0M | 623.0M |
| IPO Year | 2017 | 2017 |
| Metric | IBEX | SLDB |
|---|---|---|
| Price | $49.40 | $6.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $42.00 | $18.71 |
| AVG Volume (30 Days) | 75.1K | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.63 | ★ 34.97 |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $644,076,000.00 | $8,094,000.00 |
| Revenue This Year | $10.59 | N/A |
| Revenue Next Year | $6.75 | N/A |
| P/E Ratio | $14.28 | ★ N/A |
| Revenue Growth | ★ 15.37 | N/A |
| 52 Week Low | $25.94 | $4.01 |
| 52 Week High | $48.17 | $11.45 |
| Indicator | IBEX | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 67.35 | 50.48 |
| Support Level | $29.07 | $6.25 |
| Resistance Level | N/A | $7.42 |
| Average True Range (ATR) | 1.79 | 0.45 |
| MACD | -0.19 | 0.13 |
| Stochastic Oscillator | 100.00 | 88.38 |
IBEX Ltd delivers business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. The company's services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital), and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare, among others, and derives maximum revenue from the United States.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.